🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cancer premium: Cancer drugs 3x more expensive than non-cancer drugs after adjusting for efficacy, prevalence, incidence & mortality. thelancet.com/journals/eclin… with @miquelsb2, Aaron Mitchell Funding: Swiss National Science Foundation Covered by El Pais shorturl.at/cpLT0 & Swiss national news:

New piece: Drugs increasingly approved for many indications. Findings indicate substantially lower R&D costs for supplemental indications compared to first indications. More public data necessary to validate findings. with Olivier Wouters LSE Health Policy jamanetwork.com/journals/jama-…

New study The Lancet Digital Health: Analysis of 510(k) predicate network of AI medical devices. Tasks of AI medical devices change over time and may raise safety issues. thelancet.com/journals/landi… Jakob Urs Mühlematter, Christian Bluethgen, Unispital_USZ funded by Swiss National Science Foundation covered by NZZ

Thinking the future of essential medicines World Health Organization (WHO). Great thoughts with incredible talents and scientific superstars

Global competition between countries on the successful development of AI technologies has emerged over the past decade, with medicine at the forefront of interest. This study finds that China dominated in terms of absolute number of trials. Read more: nejm.ai/40AE2re

New study geographic representation of trials for AI med devices NEJM AI: 97% national. Approx half in China, followed by US & Japan nejm.ai/40AE2re. Funded by Swiss National Science Foundation Covered by Swiss National News SRF News Georg Halter w/ @FrauenfelderTh srf.ch/news/schweiz/n…

Neujahr ist die Zeit für neue Regeln – jedes Jahr treten Hunderte davon in Kraft. Doch wer ist dafür verantwortlich, und wo wird am meisten vorgeschrieben? Ein Zürcher Forschungsteam hat dies untersucht. Von Daniel Gerny nzz.ch/schweiz/es-gib…

Happy to share our new perspective article in The Lancet Oncology highlighting shortages of #essential (and #curative) #cancer medicines thelancet.com/journals/lanon… Kudos to amazing co-authors Kristina Jenei Kerstin Noëlle Vokinger Surgery and Cancer University of Zurich LSE Health Policy Imperial College London

Viewpoint compares use and costs of GLP-1 receptor agonists for weight loss between the US and 3 other peer countries. ja.ma/3LnIfI2

Drug prices declined substantially after patent expiration across 8 high-income countries, from 30% to 80% during the 8 years after patent expiration. ja.ma/3yDG4NV Kerstin Noëlle Vokinger

New study Annals of Int Med We assessed time from approval until reimbursement of new drugs in US, Germany, England, France, and Switzerland (2011-2022) Camille Glaus, @miquelsb2, Stacie Dusetzina With coverage NZZ tinyurl.com/26jgq23c

Kerstin Noëlle Vokinger: “Las nuevas terapias contra el cáncer son aprobadas para perfiles de pacientes no incluidos en los ensayos” Investigadores de Zurich, Yale y Harvard revelan diferencias que pueden reducir la seguridad y eficacia elpais.com/sociedad/2024-… vía EL PAÍS

🗞️Kerstin Noëlle Vokinger: ‘New cancer therapies are being approved for patient groups not included in clinical trials’ Read more 👇 english.elpais.com/health/2024-09…

Was sie mit den steigenden Krankenkassenprämien zu tun hat: Die Angstgegnerin – eine Professorin legt sich mit der Pharmabranche an nzz.ch/schweiz/der-ph…

New study The Lancet WHO shapes priorities for the world’s most influential medicines list? We analyzed applicants for WHO essential medicines list and discuss solutions to improve access to essential medicines thelancet.com/journals/lance… w/ Kristina Jenei Camille Glaus

Viewpoint from James Hillis, Edward Scheffer Cliff, and Kerstin Noëlle Vokinger: The FDA's recent authorization of an AI-powered medical device for dementia prognosis marks a step in the regulation and clinical implementation of #AI in healthcare. ja.ma/4fwUX4N